Summary

Meet our Team by visiting our virtual booth and listen to our talk during The Bioprocessing Summit Europe !

Our team

 Mégane Denu 
 R&D Engineer Bioproduction 
About Mégane Denu
R&D Engineer Bioproduction
Aucune information.
 Julien Depollier 
 Director Strategic Partnerships 
About Julien Depollier
Director Strategic Partnerships
Aucune information.
 Jean-Thomas ISSENHUTH 
 Key Account Manager 
About Jean-Thomas ISSENHUTH
Key Account Manager
Aucune information.
 Jelena Vjetrovic 
 Key Account Manager 
About Jelena Vjetrovic
Key Account Manager
Aucune information.
 Maxime Dumont 
 Product Manager 
About Maxime Dumont
Product Manager
Aucune information.
 Malik Hellal 
 Senior Scientist in Chemistry 
About Malik Hellal
Senior Scientist in Chemistry
Aucune information.

Talk

A next-generation transfection reagent for large scale rAAV manufacturing.

The number of ATMP therapeutic-based medicines for inherited genetic disorders is in constant growth, with a global 32% increase in new clinical trials in the last 4 years. ATMPs have demonstrated their success with already more than ten approved for commercialization. The success of AAV as the most promising viral vector for gene therapy is due to low immunogenicity, broad tropism and non-integrating properties. One major challenge for translation of promising research to clinical development is the manufacture of sufficient quantities of AAV. Transient transfection of suspension cells is the most commonly used production platform, as it offers significant flexibility for cell and gene therapy development. However, this method shows some limitations in large scale bioreactors: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on the novel transfection reagent showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale. The aforementioned optimized parameters make this novel transfection reagent ideal for cell and gene therapy developers by combining the flexibility of transient transfection with scalability and speed to market.

Presented by Mégane Denu, Research Engineer in Bioprodcution at Polyplus-transfection®
Wednesday, March 17th at 11:25 am – 11:45 am CET

 

Poster

Next-Generation Transfection Reagent for Large Scale AAV Manufacturing

Mathieu Porte, Mégane Denu, Jonathan Havard, Marine Ricordel, Coralie Stritt, Yann Philipson, Malik Hellal, Patrick Erbacher

 

Our solutions for both protein and virus production

FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.

PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.

FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).

General information

Registration link for virtual event: click here
Give your feedback!